Intellectual Property 2023-09-28 11:31 am | Melbourne
Save (0) Please login to bookmark Close Username or Email Address Password Remember Me Sanofi has lost its bid to limit evidence from experts for Amgen in a patent dispute over a cholesterol-lowering antibody, with a judge dismissing concerns about Amgen having a majority of experts giving concurrent evidence. In an application filed at the…